Bifidobacterium bifidum PRL2010 alleviates intestinal ischemia/reperfusion injury

Sabrina Duranti,Valentina Vivo,Irene Zini,Christian Milani,Marta Mangifesta,Rosaria Anzalone,Leonardo Mancabelli,Alice Viappiani,Anna Maria Cantoni,Elisabetta Barocelli,Douwe van Sinderen,Simona Bertoni,Francesca Turroni
DOI: https://doi.org/10.1371/journal.pone.0202670
IF: 3.7
2018-08-30
PLoS ONE
Abstract:Mesenteric ischemia/reperfusion is a clinical emergency with high morbidity and mortality due to the transient reduction of blood supply to the bowel. In recent years, the critical contribution of gut microbiome to human health and proper gastrointestinal functions has gradually emerged. In the current study, we investigated the protective effects of five days supplementation with Bifidobacterium bifidum PRL2010 in a murine model of gut ischemia/reperfusion. Our findings indicate that animals pretreated with B. bifidum PRL2010 showed lower neutrophil recruitment in the lungs, remarkably reduced bacterial translocation and decreased transcription levels of TNFalpha and IL-10 both in liver and kidneys, at the same time increasing those of IL-12 in kidneys. Inhibiting the adhesion of pathogenic bacteria and boosting host innate immunity responses are among the possible protective mechanisms enacted by the probiotic. These results demonstrate that short-period treatment with B. bifidum PRL2010 is a potential strategy to dampen remote organ injury due to mesenteric ischemia/reperfusion.
What problem does this paper attempt to address?